Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1840 1
1875 1
1878 2
1888 1
1889 2
1891 1
1896 1
1898 1
1906 1
1913 1
1915 1
1916 1
1917 1
1920 2
1922 1
1930 1
1931 1
1932 1
1935 1
1938 3
1939 1
1940 2
1941 5
1943 7
1944 2
1945 7
1946 10
1947 16
1948 16
1949 5
1950 10
1951 13
1952 10
1953 10
1954 17
1955 11
1956 8
1957 8
1958 11
1959 11
1960 11
1961 10
1962 8
1963 12
1964 14
1965 20
1966 21
1967 34
1968 31
1969 48
1970 38
1971 35
1972 33
1973 35
1974 26
1975 32
1976 42
1977 44
1978 33
1979 38
1980 43
1981 63
1982 60
1983 48
1984 47
1985 49
1986 52
1987 61
1988 69
1989 68
1990 55
1991 80
1992 74
1993 80
1994 102
1995 102
1996 83
1997 90
1998 91
1999 103
2000 132
2001 152
2002 164
2003 191
2004 173
2005 227
2006 279
2007 282
2008 290
2009 321
2010 318
2011 366
2012 407
2013 401
2014 396
2015 415
2016 465
2017 514
2018 491
2019 522
2020 585
2021 653
2022 649
2023 611
2024 594
2025 653
2026 122

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11,242 results

Results by year

Filters applied: . Clear all
Page 1
Skin damage signals mediate allergic sensitization to spatially unlinked antigen.
Waizman DA, Brown-Soler I, Martin AL, Ma Y, Zhou K, Israni-Winger K, Zhang C, Medzhitov R, Launay P, Michieletto MF, Henao-Mejia J, Palm NW, Craft J, Eisenstein A, Wang A. Waizman DA, et al. Among authors: martin al. Sci Immunol. 2025 Apr 4;10(106):eadn0688. doi: 10.1126/sciimmunol.adn0688. Epub 2025 Apr 4. Sci Immunol. 2025. PMID: 40184440 Free PMC article.
Architecture of the neutrophil compartment.
Cerezo-Wallis D, Rubio-Ponce A, Richter M, Pitino E, Kwok I, Marteletto G, Guanolema-Coba AC, Shih C, Huang RK, Moraga A, Bravo NB, Doré S, Callejas S, Aragonés DG, Jiménez-Carretero D, Martin D, Ovadia S, Vicanolo T, Crainiciuc G, Sicilia J, Deng T, Martin A, Zhang J, Cuartero MI, Giraldo DM, Garcia-Culebras A, Aroca-Crevillen A, Martín-Salamanca S, Torroja C, Ruiz M, Ruano I, Ng MSF, Hou J, Wang Y, Zhang M, Pu J, Herruzo A, van Oordt DC, Chang S, Downie AE, Chen F, Graham AL, Gause WC, Fiset PO, Spicer JD, Heyn H, Zuriaga MA, Bernal JA, Udalova IA, Moro MA, de Bock K, Dopazo A, Fuster JJ, Sánchez-Cabo F, Nieto JC, Calvo GF, Skokowa J, Soehnlein O, Quail DF, Walsh LA, Ng LG, Hidalgo A, Ballesteros I. Cerezo-Wallis D, et al. Among authors: martin a. Nature. 2026 Jan;649(8098):1003-1012. doi: 10.1038/s41586-025-09807-0. Epub 2025 Dec 3. Nature. 2026. PMID: 41339555 Free PMC article.
The changing prevalence of ADHD? A systematic review.
Martin AF, Rubin GJ, Rogers MB, Wessely S, Greenberg N, Hall CE, Pitt A, Logan PE, Lucas R, Brooks SK. Martin AF, et al. J Affect Disord. 2025 Nov 1;388:119427. doi: 10.1016/j.jad.2025.119427. Epub 2025 May 18. J Affect Disord. 2025. PMID: 40393551 Free article.
Dupilumab versus omalizumab in patients with chronic rhinosinusitis with nasal polyps and coexisting asthma (EVEREST): a multicentre, randomised, double-blind, head-to-head phase 4 trial.
De Corso E, Canonica GW, Heffler E, Springer M, Grzegorzek T, Viana M, Horváth Z, Mullol J, Gevaert P, Michel J, Peters AT, Wagenmann M, Zaghloul S, Zhang M, Corbett M, Nash S, Angello JT, Radwan A, Deniz Y, Martin A, Hellings PW. De Corso E, et al. Among authors: martin a. Lancet Respir Med. 2025 Dec;13(12):1067-1077. doi: 10.1016/S2213-2600(25)00287-5. Epub 2025 Sep 28. Lancet Respir Med. 2025. PMID: 41033334 Clinical Trial.
Profiling antigen-binding affinity of B cell repertoires in tumors by deep learning predicts immune-checkpoint inhibitor treatment outcomes.
Song B, Wang K, Na S, Yao J, Fattah FJ, Martin AL, von Itzstein MS, Yang DM, Liu J, Xue Y, Liang C, Guo Y, Raman I, Zhu C, Dowell JE, Homsi J, Rashdan S, Yang S, Gwin ME, Wu T, Hsiehchen D, Gloria-McCutchen Y, Lu CP, Raj P, Bai XC, Wang J, Conejo-Garcia J, Xie Y, Huang J, Gerber DE, Wang T. Song B, et al. Among authors: martin al. Nat Cancer. 2025 Sep;6(9):1570-1584. doi: 10.1038/s43018-025-01001-5. Epub 2025 Jun 27. Nat Cancer. 2025. PMID: 40579590
Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial.
Emmett L, Papa N, Subramaniam S, Crumbaker M, Nguyen A, Joshua AM, Sandhu S, Weickhardt A, Lee ST, Ng S, Francis RJ, Goh JC, Pattison DA, Tan TH, Kirkwood ID, Ayati N, Niu C, Hofman MS, Martin AJ, Thomas H, Davis ID, Stockler MR; ENZA-p Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Emmett L, et al. Among authors: martin aj. Lancet Oncol. 2025 Sep;26(9):1168-1177. doi: 10.1016/S1470-2045(25)00339-0. Epub 2025 Jul 30. Lancet Oncol. 2025. PMID: 40752515 Clinical Trial.
Genomic loci and molecular genetic mechanisms for hidradenitis suppurativa.
Broadaway KA, Sun Q, Edmiston SN, Currin KW, Vadlamudi S, Miller-Fleming TW, Shi Y, Fajgenbaum K, Melendez-Gonzalez M, Bui H, Blum FR, Westerkam L, Shams R, Mallela T, Levitt B, Lin L, Hao H, Memili A, Straub P, Zhou W, Harris KM, Martin A, Cox NJ, Liu Z, Thomas NE, Li Y, Mohlke KL, Sayed CJ. Broadaway KA, et al. Among authors: martin a. Br J Dermatol. 2025 Oct 17;193(5):948-958. doi: 10.1093/bjd/ljaf277. Br J Dermatol. 2025. PMID: 40650879 Free PMC article.
Genomic landscape of diffuse glioma revealed by whole genome sequencing.
Kinnersley B, Jung J, Cornish AJ, Chubb D, Laxton R, Frangou A, Gruber AJ, Sud A, Caravagna G, Sottoriva A, Wedge DC, Booth T, Al-Sarraj S, Lawrence SED, Albanese E, Anichini G, Baxter D, Boukas A, Chowdhury YA, D'Urso P, Corns R, Dapaah A, Edlmann E, Greenway F, Grundy P, Hill CS, Jenkinson MD, Trichinopoly Krishna S, Smith S, Manivannan S, Martin AJ, Matloob S, Mukherjee S, O'Neill K, Plaha P, Pollock J, Price S, Rominiyi O, Sachdev B, Saeed F, Sinha S, Thorne L, Ughratdar I, Whitfield P, Youshani AS, Bulbeck H, Arumugam P, Houlston R, Ashkan K. Kinnersley B, et al. Among authors: martin aj. Nat Commun. 2025 May 7;16(1):4233. doi: 10.1038/s41467-025-59156-9. Nat Commun. 2025. PMID: 40335506 Free PMC article.
Intensity-modulated moderately hypofractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-C): early toxicity results from a randomised, open-label, phase 3, non-inferiority trial.
Tree AC, Hinder V, Chan A, Tolan S, Ostler P, van der Voet H, Kancherla K, Loblaw A, Naismith O, Jain S, Martin A, Price D, Brand D, Chu W, Duffton A, Kelly P, O'Neill B, Staffurth J, Sasso G, Pugh J, Manning G, Brown S, Burnett S, Griffin C, Hall E, van As N; PACE Investigators. Tree AC, et al. Among authors: martin a. Lancet Oncol. 2025 Jul;26(7):936-947. doi: 10.1016/S1470-2045(25)00205-0. Epub 2025 Jun 12. Lancet Oncol. 2025. PMID: 40517778 Free PMC article. Clinical Trial.
11,242 results
You have reached the last available page of results. Please see the User Guide for more information.